Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.69 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CCR8 | P51685 | 2/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ME3 | Q16798 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22499995 | 1.00 | MTNR1A (0.69) | MTNR1AMTNR1BSIGMAR1MCHR1EPHX2 | |
| SCHEMBL23387200 | 0.87 | MTNR1A (0.52) | MTNR1AMTNR1B | |
| SCHEMBL23387198 | 0.87 | MTNR1A (0.52) | MTNR1AMTNR1B | |
| SCHEMBL21624749 | 0.86 | ME3 (0.51) | MTNR1AMTNR1BSIGMAR1LMNAME3 | |
| SCHEMBL21624746 | 0.86 | ME3 (0.51) | MTNR1AMTNR1BSIGMAR1LMNAME3 | |
| SCHEMBL1967518 | 0.84 | MTNR1A (0.83) | MTNR1AMTNR1BSIGMAR1MCHR1CCR8 | |
| SCHEMBL1964369 | 0.84 | MTNR1A (0.83) | MTNR1AMTNR1BSIGMAR1MCHR1CCR8 | |
| SCHEMBL29689580 | 0.84 | MTNR1A (0.52) | MTNR1AMTNR1B | |
| SCHEMBL10324092 | 0.82 | MTNR1B (1.00) | MTNR1AMTNR1BSIGMAR1NPY5RLMNA | |
| SCHEMBL10324093 | 0.82 | MTNR1B (1.00) | MTNR1AMTNR1BSIGMAR1NPY5RLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-11-17 | — | — | US | claimed |
| EP-3825303-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nippon Chemiphar Co., Ltd. (JP) | 2021-05-26 | — | — | EP | claimed |
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-11-17 | — | — | US | disclosed |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-07-21 | — | — | US | disclosed |
| EP-3950059-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | Nippon Chemiphar Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| EP-3825303-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nippon Chemiphar Co., Ltd. (JP) | 2021-05-26 | — | — | EP | disclosed |
| WO-2020203610-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING RHEUMATOID ARTHRITIS | 日本ケミファ株式会社 | 2020-10-08 | — | — | WO | disclosed |
| WO-2020203609-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | 日本ケミファ株式会社 | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1I, CACNA1G, CACNA1H | MTNR1A 681/4885MTNR1B 398/4885SIGMAR1 732/4885 |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | TRPV3, CACNA1G, TRPV2 | MTNR1A 832/4885MTNR1B 557/4885SIGMAR1 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.